Format

Send to

Choose Destination
Semin Oncol. 2014 Feb;41(1):110-25. doi: 10.1053/j.seminoncol.2013.12.006. Epub 2013 Dec 12.

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Author information

1
Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO. Electronic address: eamon.berge@ucdenver.edu.
2
Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO.

Abstract

The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) gene in a subset of NSCLC patients. Several additional oncogenic mutations, including gene fusions and amplifications, have since been discovered, with a number of drugs that target each specific oncogene. This review focuses on oncogenes in NSCLC other than EGFR and their companion "targeted therapies." Particular emphasis is placed on the role of ALK, ROS1, RET, MET, BRAF, and HER2 in NSCLC.

PMID:
24565585
PMCID:
PMC4159759
DOI:
10.1053/j.seminoncol.2013.12.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center